Mass spectrometric investigations into the brain delivery of abacavir, stavudine and didanosine in a rodent model

Mdanda, Sipho; Ntshangase, Sphamandla; Singh, Sima; Naicker, Tricia; Kruger, Hendrik G.; Baijnath, Sooraj; Govender, Thavendran

doi:10.1080/00498254.2019.1655605

Cited by 2 publications

(1 citation statement)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contrary to this observation, however, Mdanda et al [72] recently demonstrated that Zidovudine and Lamivudine, both of which belong to the class of nucleoside reverse transcriptase inhibitors (NRTIs), are both able to reach and localize in the brain regions that are targets of HIV neurodegeneration in the CNS using a Sprague-Dawley rat model. In a different set of experiments, Mdanda et al [73] most recently also reported that alternative NRTIs, including Abacavir and Stavudine, were able to reach the brain regions that are strongly implicated in the progression of HAND, while Didanosine exhibited poor entry within the brain, suggesting that it is not recommended for the treatment of neuro-HIV infection. Thomas [71] also observed that non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as Nevirapine and Efavirenz can readily enter the CSF.…”

Section: Neuro-hiv Drugs and Therapy In The Cnsmentioning

confidence: 99%

Human Immunodeficiency Virus Type-1 (HIV-1) Transcriptional Regulation, Latency and Therapy in the Central Nervous System

Hokello

Sharma

Tyagi³

et al. 2021

Vaccines

View full text Add to dashboard Cite

The central nervous system (CNS) is highly compartmentalized and serves as a specific site of human immunodeficiency virus (HIV) infection. Therefore, an understanding of the cellular populations that are infected by HIV or that harbor latent HIV proviruses is imperative in the attempts to address cure strategies, taking into account that HIV infection and latency in the CNS may differ considerably from those in the periphery. HIV replication in the CNS is reported to persist despite prolonged combination antiretroviral therapy due to the inability of the current antiretroviral drugs to penetrate and cross the blood–brain barrier. Consequently, as a result of sustained HIV replication in the CNS even in the face of combination antiretroviral therapy, there is a high incidence of HIV-associated neurocognitive disorders (HAND). This article, therefore, provides a comprehensive review of HIV transcriptional regulation, latency, and therapy in the CNS.

show abstract

Section: Neuro-hiv Drugs and Therapy In The Cnsmentioning

confidence: 99%